Pluri Inc. Other Selling, General and Administrative Expense
Pluri Inc. (PLUR) reported Other Selling, General and Administrative Expense of $1.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherSellingGeneralAndAdministrativeExpense · last filed 2024-05-09
- Pluri Inc. other selling, general and administrative expense for the quarter ending 2023-03-31 was $1.00K, a 88.89% decline year-over-year.
- Pluri Inc. other selling, general and administrative expense for the quarter ending 2022-12-31 was -$6.00K, a 175.00% decline year-over-year.
- Pluri Inc. other selling, general and administrative expense for the quarter ending 2022-09-30 was $12.00K, a 500.00% increase year-over-year.
- Pluri Inc. other selling, general and administrative expense for the quarter ending 2022-03-31 was $9.00K, a 200.00% increase year-over-year.
| Period end | Other Selling, General and Administrative Expense 3 month | Other Selling, General and Administrative Expense 6 month | Other Selling, General and Administrative Expense 9 month |
|---|---|---|---|
| 2023-03-31 | $1.00K 10-Q · filed 2024-05-09 | -$5.00K derived: sum of 2 quarters · filed 2024-05-09 | $5.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-13 | $6.00K 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $12.00K 10-Q · filed 2022-11-10 | ||
| 2022-03-31 | $9.00K 10-Q · filed 2023-05-09 | $17.00K derived: sum of 2 quarters · filed 2023-05-09 | $29.00K 10-Q · filed 2023-05-09 |
| 2021-12-31 | $8.00K 10-Q · filed 2023-02-13 | $10.00K 10-Q · filed 2023-02-13 | |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-10 | ||
| 2021-03-31 | $3.00K 10-Q · filed 2022-05-09 | $6.00K derived: sum of 2 quarters · filed 2022-05-09 | $19.00K 10-Q · filed 2022-05-09 |
| 2020-12-31 | $3.00K 10-Q · filed 2022-02-07 | $6.00K 10-Q · filed 2022-02-07 | |
| 2020-09-30 | $3.00K 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |